Clinical practice for migraine treatment and characteristics of medical facilities and physicians treating migraine: Insights from a retrospective cohort study using a Japanese claims database.

Autor:	Takizawa T; Department of Neurology, Keio University School of Medicine, Tokyo, Japan., Kitano T; Japan Access & Value, Pfizer Japan Inc., Tokyo, Japan., Togo K; Japan Access & Value, Pfizer Japan Inc., Tokyo, Japan., Yoshikawa R; Internal Medicine, Hospital, and Antiviral Medical Affairs, Pfizer Japan Inc., Tokyo, Japan., Iijima M; Internal Medicine, Hospital, and Antiviral Medical Affairs, Pfizer Japan Inc., Tokyo, Japan.
Jazyk:	angličtina
Zdroj:	PloS one [PLoS One] 2024 Dec 19; Vol. 19 (12), pp. e0315610. Date of Electronic Publication: 2024 Dec 19 (Print Publication: 2024).
DOI:	10.1371/journal.pone.0315610
Abstrakt:	The real-world treatment patterns at medical facilities and their physicians' specialties treating migraine have not been fully investigated in Japan. Therefore, a retrospective cohort study aimed to describe real-world clinical practice and treatment patterns in Japanese patients with migraine according to medical facilities and physicians' specialties. Anonymized claims data of patients with migraine was obtained from JMDC Inc (January 2018-June 2023). Patient characteristics and treatment pattern according to medical facilities and physicians' specialties treating migraine were evaluated. Of 231,156 patients with migraine (mean age [SD], 38.8 [11.8] years; females, 65.3%), 81.8% had the first prescription at clinics (CPs), 42.5% underwent imaging tests, 44.4% visited general internal medicine, and 25.9% consulted neurosurgery at initial diagnosis. Imaging tests were carried out at CPs with specialists (59.4%), hospitals (HPs) with specialists (59.1%), HPs (32.9%), and CPs (26.9%) without specialists. Overall, 95.6% received acute treatment while 21.8% received preventive treatment. At facilities with specialists compared to without specialists, triptans were more frequently prescribed (67.9% vs 44.9%) whereas acetaminophen and nonsteroidal anti-inflammatory drugs were less frequently prescribed (52.4% vs 69.2%). Preventive treatment use was higher at facilities with specialists (27.4%) than without specialists (15.7%) and increased annually regardless of the type of medical institution. In Japan, only half of patients with migraine visited facilities with specialists at their first diagnosis, and specialists are more likely use migraine-specific and preventive drugs than nonspecialists. Therefore, there is a need for awareness among migraine patients that they should consult specialists and for enhancement of medical collaboration between specialists and nonspecialists. Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: TT is a consultant/advisor and/or serves on an advisory board for Pfizer, Eli Lilly, Otsuka, Amgen, and Teijin and has received speaker honoraria from Eli Lilly, Daiichi Sankyo, Otsuka, Amgen, Kowa, Kyowa Kirin, Eisai, UCB Japan, Takeda, and Santen Pharmaceutical and grant from Pfizer and research funding from Eli Lilly and Tsumura outside the submitted work. TK, KT, RY, and MI are employees of Pfizer Japan (Tokyo, Japan). KT and MI are shareholders of Pfizer Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. This commercial affiliation, Pfizer Japan Inc., does not alter our adherence to PLOS ONE policies on sharing data and materials. (Copyright: © 2024 Takizawa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu